Consistent OS Efficacy Benefit Across Multiple Treatment Subgroups Demonstrates IMNN-001’s Ability to Recruit a Powerful Anti-Cancer Immune Response Results, presented...
REDWOOD CITY, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company...
This collaboration sets out to explore whether using the Matter Neuroscience protocol combined with real-time neurofeedback can influence emotional brain networks...
Highly experienced biopharma executive Dr Cristina Csimma joins Asgard's Board of Directors, while esteemed immunologists Prof Ignacio Melero and Prof...
Contributing to high-definition visualization of cellular activity and supporting research into neuronal and cardiac diseases and drug discovery TOKYO, June...
Philadelphia, Pennsylvania--(Newsfile Corp. - June 2, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) (the "Company") today announced the closing of...
INDIANAPOLIS, June 2, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Goldman Sachs 46th Annual Global...
NASHVILLE, Tenn. and SAN ANTONIO, June 2, 2025 /PRNewswire/ -- OneOncology, a physician-led national platform empowering independent oncology practices, and...
Peer-reviewed journal article highlights need for personalized, culturally relevant approaches to cognitive care and research BOSTON, June 2, 2025 /PRNewswire/...
PETACH TIKVA, Israel, June 2, 2025 /PRNewswire/ -- ASP Isotopes Inc. (NASDAQ: ASPI) and Isotopia Molecular Imaging Ltd. have entered...
-Clinical benefit and favorable safety profile as monotherapy and in combination with SOC- -Biomarker data supports MOA: decreased GBM mesenchymal...
- Expert Insights on Clinical Relevance and Scientific Rationale- The replay of the event is available on the Investor Relations...
Rapid commercial validation has been achieved through key partnerships disrupting high value/high growth marketsLeadership team realigned in order to enable...
All dollar amounts reflected in Canadian dollars unless otherwise statedVANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics...
Presentation highlights deep and durable responses and radiographic resolution of bone metastases in patients with advanced prostate cancer Final clinical...
31% confirmed ORR (8 responses in 26 evaluable patients) across B7-H4 high tumors at intermediate doses 44% confirmed ORR (7...
Outstanding Phase 2 Results will be discussed at the 2025 ASCO in an Oral Presentation and featured in peer reviewed...
Vancouver, British Columbia--(Newsfile Corp. - June 2, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical" or the "Company"),...
The AI-enabled clinical assistant is available to query patient data across the EHR as well as build custom agents to...
33% reduction in relative risk of invasive disease observed in pre-menopausal early breast cancer (EBC) patients receiving Kisqali in 1-year...